SCHEMBL7533892

SCHEMBL7533892

CCCCOc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.77
LMNA P02545 5/20 0.77
ALDH1A1 P00352 2/20 0.75
MAPT P10636 2/20 0.75
CYP2C9 P11712 2/20 0.75
CYP2C19 P33261 2/20 0.75
ESR1 P03372 5/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
PGR P06401 2/20 0.71
AR P10275 2/20 0.71
SLC6A3 Q01959 2/20 0.71
ADORA3 P0DMS8 2/20 0.71
ATM Q13315 2/20 0.71
ABCC1 P33527 1/20 0.71
ABCC4 O15439 1/20 0.71
CHRM1 P11229 1/20 0.71
TBXA2R P21731 1/20 0.71
ADRA1A P35348 1/20 0.71
OPRM1 P35372 1/20 0.71
STS P08842 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18487958 1.00 HSD17B10 (0.77) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL18541855 1.00 HSD17B10 (0.77) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL10615356 0.98 HSD17B10 (0.74) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL7537644 0.97 HSD17B10 (0.72) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL18687578 0.97 HSD17B10 (0.75) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL28503910 0.97 HSD17B10 (0.75) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL19732547 0.96 HSD17B10 (0.71) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL21338341 0.96 HSD17B10 (0.71) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL21338329 0.93 HSD17B10 (0.70) HSD17B10LMNAALDH1A1MAPTCYP2C9
SCHEMBL17972779 0.93 HSD17B10 (0.70) HSD17B10LMNAALDH1A1MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9687556-B2 Compounds and methods for trans-membrane delivery of molecules APOSENSE LTD. (IL) 2017-06-27 US disclosed
US-20170100486-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD. (IL) 2017-04-13 US disclosed
US-20170080095-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD. (IL) 2017-03-23 US disclosed
US-20170037401-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD. (IL) 2017-02-09 US disclosed
WO-2017017669-A1 PRO-DRUGS AND RELATED METHODS APOSENSE LTD. (IL) 2017-02-02 WO disclosed
US-20160129125-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD. (IL) 2016-05-12 US disclosed
US-20160120996-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD. (IL) 2016-05-05 US disclosed
US-20160106855-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD. (IL) 2016-04-21 US disclosed
US-20020035100-A1 Alkyl ether modified polycyclic compounds having a terminal phenol and uses for protection of cells UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170080095-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES ABCB4, LNPK, MBOAT1 HSD17B10 3759/4885LMNA 232/4885ALDH1A1 3993/4885
US-20160129125-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES ABCB4, LNPK, NPC1L1 HSD17B10 3671/4885LMNA 243/4885ALDH1A1 3911/4885
US-20170100486-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES ABCB4, LNPK, MBOAT1 HSD17B10 3759/4885LMNA 232/4885ALDH1A1 3993/4885
US-20160106855-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES ABCB4, LNPK, NPC1L1 HSD17B10 3671/4885LMNA 243/4885ALDH1A1 3911/4885
US-20160120996-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES ABCB4, LNPK, MBOAT1 HSD17B10 3759/4885LMNA 232/4885ALDH1A1 3993/4885
US-20170037401-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES ABCB4, LNPK, MBOAT1 HSD17B10 3759/4885LMNA 232/4885ALDH1A1 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.